ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

Growth Factors, Cell Receptors, Intracellular Kinases, and Transcription Factors Associated with Clinical Anxiety

AJ Russo[1]*, Albert Mensah[2] and Judith Bowman[2]

[1]*Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA*

[2]*Mensah Research Institute, Warrenville, Il, USA*

***Corresponding Author:** AJ Russo, Visiting Professor, Hartwick College, Oneonta, NY and Research Director, Mensah Research Institute, Warrenville, Il, USA.

Received: December 16, 2024; **Published:** March 11, 2025

Abstract

Clinical anxiety is a prevalent mental health condition characterized by excessive fear and worry that can significantly impair daily functioning. Growth factors, such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF), and vascular endothelial growth factor (VEGF), have been implicated in the pathophysiology of anxiety disorders. Cell receptors, such as Corticotropin-releasing hormone (CRH) receptors, mediate the actions of neurotransmitters and neuropeptides that are crucial in regulating mood and anxiety responses. At the molecular level, intracellular kinases play a pivotal role in modulating the neural circuits associated with anxiety. Among these kinases, the mitogen-activated protein kinases (MAPKs), particularly the extracellular signal-regulated kinases (ERK1/2), and transcription factors, such as the cAMP response element-binding protein (CREB) play a crucial role in regulating gene expression related to stress responses, emotional regulation, and neuroplasticity and may be associated with the etiology of anxiety. This report summarizes some of the major growth factors, cell receptors, intracellular kinases, and transcription factors that may be associated with the etiology of clinical anxiety.

Keywords: *Brain-Derived Neurotrophic Factor (BDNF); Insulin-Like Growth Factor (IGF); Vascular Endothelial Growth Factor (VEGF); Corticotropin-Releasing Hormone (CRH); Mitogen-Activated Protein Kinases (MAPKs); Extracellular Signal-Regulated Kinases (ERK1/2); cAMP Response Element-Binding Protein (CREB)*

Growth factors associated with clinical anxiety

Clinical anxiety is a prevalent mental health condition characterized by excessive fear and worry that can significantly impair daily functioning. Understanding the biological underpinnings of anxiety, particularly the role of growth factors, is crucial for developing effective interventions. Growth factors, such as brain-derived neurotrophic factor (BDNF), insulin-like growth factor (IGF), and vascular endothelial growth factor (VEGF), have been implicated in the pathophysiology of anxiety disorders. This synthesis will explore the associations between these growth factors and clinical anxiety, drawing on a range of studies that highlight their roles.

BDNF is a neurotrophin that plays a critical role in neuronal survival, growth, and differentiation. It is particularly important in the context of synaptic plasticity, which is essential for learning and memory. Research has shown that alterations in BDNF signaling are associated with anxiety disorders. For instance, lower levels of BDNF have been observed in individuals with anxiety, suggesting that

deficits in this growth factor may contribute to the development and maintenance of anxiety symptoms [1]. Furthermore, animal studies have demonstrated that BDNF deficiency can lead to increased anxiety-like behaviors, reinforcing the notion that BDNF is a key player in anxiety pathophysiology [1].

The signaling pathways activated by BDNF, particularly the phosphoinositide 3-kinase (PI3K) pathway, are also implicated in anxiety. The activation of this pathway can lead to the modulation of neurotransmitter systems, including serotonin and dopamine, which are critical in regulating mood and anxiety [1]. Moreover, the interaction between BDNF and stress hormones, such as cortisol, further complicates the relationship between BDNF levels and anxiety. Chronic stress can lead to decreased BDNF expression, which may exacerbate anxiety symptoms [1].

Insulin-like growth factor (IGF) is another growth factor that has been linked to anxiety disorders. IGF signaling is involved in neurogenesis and synaptic plasticity, similar to BDNF. Studies have indicated that alterations in IGF levels may be associated with anxiety and depressive symptoms. For example, research has shown that IGF-1 levels are significantly lower in individuals with anxiety disorders compared to healthy controls [2]. This suggests that IGF may play a protective role against the development of anxiety, and its deficiency could contribute to the onset of anxiety disorders.

The relationship between IGF and anxiety may also involve the modulation of neuroinflammatory processes. Elevated levels of pro-inflammatory cytokines have been associated with anxiety, and IGF has been shown to exert anti-inflammatory effects. This indicates that IGF may help mitigate the neuroinflammatory responses that can contribute to anxiety symptoms [2]. Furthermore, the interaction between IGF and other growth factors, such as BDNF, highlights the complexity of the neurobiological mechanisms underlying anxiety disorders.

Vascular endothelial growth factor (VEGF) is primarily known for its role in angiogenesis, but it also plays a significant role in neuroprotection and neurogenesis. Recent studies have suggested that VEGF may be involved in the regulation of anxiety. For instance, increased levels of VEGF have been associated with reduced anxiety-like behaviors in animal models [3]. This suggests that VEGF may exert anxiolytic effects, potentially through its ability to promote neurogenesis and enhance synaptic plasticity.

Moreover, the relationship between VEGF and anxiety may be mediated by its effects on the hypothalamic-pituitary-adrenal (HPA) axis, which is crucial in the body's response to stress. Dysregulation of the HPA axis is commonly observed in individuals with anxiety disorders, and VEGF may help modulate this response [3]. The interplay between VEGF and stress-related hormones, such as cortisol, further underscores the importance of this growth factor in the context of anxiety.

In addition to these specific growth factors, the broader context of psychosocial factors and their interaction with biological mechanisms is essential in understanding anxiety. Studies have shown that maternal anxiety and rearing behaviors can influence the development of anxiety symptoms in children, highlighting the role of environmental factors alongside biological predispositions [4]. This suggests that interventions targeting both growth factors and psychosocial factors may be necessary for effective anxiety treatment.

Furthermore, the impact of lifestyle factors, such as physical activity and diet, on growth factor levels and anxiety symptoms cannot be overlooked. Regular physical activity has been shown to increase BDNF levels, which may help alleviate anxiety symptoms [1]. Similarly, dietary factors that influence growth factor signaling, such as omega-3 fatty acids, have been associated with improved mood and reduced anxiety [1].

In conclusion, growth factors such as BDNF, IGF, and VEGF play significant roles in the pathophysiology of clinical anxiety. Their involvement in neurogenesis, synaptic plasticity, and the modulation of neuroinflammatory processes highlights the complexity of anxiety

disorders. Future research should continue to explore the interactions between these growth factors and psychosocial factors, as well as the potential for targeted interventions that can enhance growth factor signaling to mitigate anxiety symptoms.

Cell receptors associated with clinical anxiety

Clinical anxiety is a complex disorder influenced by various neurobiological factors, including the roles of specific cell receptors. These receptors mediate the actions of neurotransmitters and neuropeptides that are crucial in regulating mood and anxiety responses. This synthesis will explore the key receptors associated with clinical anxiety, focusing on neuropeptide Y (NPY) receptors, corticotropin-releasing hormone (CRH) receptors, serotonin receptors, and GABA receptors.

Neuropeptide Y (NPY) is a 36-amino acid peptide that plays a significant role in modulating anxiety and stress responses. The expression of NPY receptors, particularly NPY1R and NPY5R, has been shown to correlate inversely with anxious temperament. Research indicates that lower anxiety levels are associated with increased expression of these receptors in the central amygdala, suggesting that NPY may exert anxiolytic effects through its receptors [5]. This relationship underscores the potential of targeting NPY receptors for therapeutic interventions in anxiety disorders.

Corticotropin-releasing hormone (CRH) receptors, specifically CRHR1 and CRHR2, are also critical in the neurobiology of anxiety. These receptors are involved in the body's stress response and are known to influence serotonin synthesis in the brain. Studies have demonstrated that chronic stress elevates CRH mRNA expression, which can lead to dysregulation of serotonin pathways, further exacerbating anxiety symptoms [6]. The differential roles of CRHR1 and CRHR2 in modulating stress responses highlight the complexity of the neuroendocrine mechanisms underlying anxiety.

Serotonin receptors, particularly the 5-HT1A and 5-HT2A subtypes, are well-established in the context of anxiety. The 5-HT1A receptor is primarily associated with anxiolytic effects, and its activation has been shown to reduce anxiety-like behaviors in various animal models [7]. Conversely, the 5-HT2A receptor has been implicated in anxiety and mood regulation, with alterations in its expression linked to anxiety disorders [8]. The serotonergic system's involvement in anxiety emphasizes the importance of serotonin receptor modulation in therapeutic strategies.

GABA receptors, particularly GABA_A and GABA_B receptors, are crucial for inhibitory neurotransmission in the central nervous system. Dysregulation of GABAergic signaling has been associated with increased anxiety. For instance, GABA_A receptor subtypes mediate the anxiolytic effects of benzodiazepines, which enhance GABAergic transmission [9]. Additionally, GABA_B receptors have been implicated in the modulation of anxiety responses, with studies suggesting that their activation can produce anxiolytic effects [10]. The interplay between GABAergic and serotonergic systems further complicates the neurobiological landscape of anxiety.

The metabotropic glutamate receptors (mGluRs) also play a role in anxiety modulation. For example, mGluR2 and mGluR3 receptors have been shown to influence anxiety-like behaviors in animal models. Agonists of these receptors can produce anxiolytic effects, indicating their potential as therapeutic targets for anxiety disorders [11]. The involvement of glutamate signaling in anxiety highlights the importance of excitatory neurotransmission in the regulation of mood and anxiety.

Furthermore, the role of the noradrenergic system in anxiety cannot be overlooked. Alpha-2 adrenergic receptors, which have a high affinity for norepinephrine, are involved in the regulation of anxiety and stress responses. Activation of these receptors can inhibit neuronal activity, thereby reducing anxiety-like behaviors [12]. The interaction between noradrenergic signaling and other neurotransmitter systems, such as serotonin and GABA, illustrates the complexity of the neurobiological mechanisms underlying anxiety.

The cannabinoid system, particularly the CB1 receptor, has also been implicated in anxiety regulation. CB1 receptors are abundant in brain regions associated with emotional processing, and their activation has been shown to modulate anxiety responses. Studies suggest that cannabinoids can produce anxiolytic effects, potentially through their interactions with GABAergic and glutamatergic systems [13]. This indicates that targeting the endocannabinoid system may offer novel therapeutic approaches for anxiety disorders.

Moreover, the role of estrogen receptors in anxiety is gaining attention. Estrogen receptor beta (ERβ) has been shown to exert anxiolytic effects, particularly in the context of hormonal fluctuations. Research indicates that activation of ERβ in specific brain regions can improve anxiety-like behaviors, suggesting that estrogen modulation may be a viable strategy for managing anxiety, especially in women [14]. This highlights the importance of considering hormonal influences in the treatment of anxiety disorders.

In addition to these specific receptors, the broader context of receptor interactions and signaling pathways is crucial in understanding anxiety. For instance, the interplay between serotonin and GABA systems, as well as the involvement of neuropeptides like NPY and CRH, creates a complex network of signaling that regulates anxiety responses. This complexity necessitates a multifaceted approach to treatment, targeting multiple receptors and pathways to achieve optimal therapeutic outcomes.

In summary, various cell receptors play significant roles in the pathophysiology of clinical anxiety. Neuropeptide Y receptors, corticotropin-releasing hormone receptors, serotonin receptors, GABA receptors, and metabotropic glutamate receptors all contribute to the regulation of anxiety and stress responses. Understanding the intricate interactions between these receptors and their signaling pathways is essential for developing effective interventions for anxiety disorders. Future research should continue to explore these relationships to identify novel therapeutic targets and improve treatment strategies for individuals suffering from anxiety.

Intracellular kinases associated with anxiety

Anxiety disorders are complex conditions influenced by a myriad of biological, psychological, and environmental factors. At the molecular level, intracellular kinases play a pivotal role in modulating the neural circuits associated with anxiety. Among these kinases, the mitogen-activated protein kinases (MAPKs), particularly the extracellular signal-regulated kinases (ERK1/2), have garnered significant attention due to their involvement in various signaling pathways that affect neuronal function, synaptic plasticity, and emotional behavior.

The ERK signaling pathway is crucial for the regulation of anxiety-like behaviors. Activation of ERK1/2 has been shown to be essential for the induction and maintenance of synaptic plasticity, which is a fundamental process underlying learning and memory. This pathway is particularly active in the basolateral amygdala (BLA) and the medial prefrontal cortex (mPFC), regions that are critically involved in the processing of emotional information and the regulation of anxiety responses [15,16]. For instance, studies have demonstrated that ERK signaling in the BLA is necessary for the acquisition and extinction of fear memories, indicating its role in anxiety-related learning processes [16,17].

In addition to ERK, other kinases such as protein kinase A (PKA) and p38 MAPK are also implicated in the modulation of anxiety. PKA, which is activated by cyclic adenosine monophosphate (cAMP), has been shown to influence stress responses and anxiety behaviors [18,19]. The p38 MAPK pathway, on the other hand, has been linked to the regulation of inflammatory responses in the brain, which can exacerbate anxiety symptoms [20]. The interplay between these kinases and their respective signaling pathways highlights the complexity of the molecular mechanisms underlying anxiety disorders.

Moreover, the role of neuroinflammation in anxiety has been increasingly recognized, with evidence suggesting that inflammatory cytokines can activate various kinase pathways, including the ERK and p38 MAPK pathways. This activation can lead to alterations in neuronal function and contribute to the development of anxiety-like behaviors [21,22]. For example, high-fat diets have been shown to induce neuroinflammation and activate mTORC1 signaling, which is associated with anxiety and depressive-like behaviors [21]. Similarly, the activation of ERK in the anterior cingulate cortex has been linked to pain-related anxiety, suggesting that chronic pain conditions may exacerbate anxiety through inflammatory pathways [23,24].

The interaction between different intracellular signaling pathways is also critical in understanding anxiety. For instance, the crosstalk between the ERK and PKA pathways can modulate the effects of stress on anxiety behaviors. Insulin signaling, which activates PKA, has been shown to influence anxiety and depression, indicating that metabolic factors can also impact the neurobiological underpinnings of anxiety [25]. Furthermore, the role of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), in activating TrkB signaling pathways has been implicated in anxiety disorders, particularly in the context of stress and trauma [26,27].

In addition to these pathways, the involvement of oxytocin and its signaling through the ERK pathway has been explored in the context of social behaviors and anxiety. Oxytocin has been shown to modulate anxiety-like behaviors in animal models, and its effects are mediated by the inhibition of ERK signaling in specific brain regions [28,29]. This suggests that neuropeptides can influence anxiety through complex signaling networks involving multiple kinases.

The differential expression of kinases in various brain regions also contributes to the variability in anxiety responses. For example, sexually dimorphic expression of ERK2 in the mPFC has been associated with differences in anxiety-like behaviors between male and female rats [29]. This highlights the importance of considering sex differences in the study of anxiety and its underlying molecular mechanisms.

In conclusion, intracellular kinases, particularly the MAPK family, play a fundamental role in the modulation of anxiety through their involvement in various signaling pathways that affect neuronal function and behavior. The intricate interplay between these kinases, neuroinflammation, and neuropeptide signaling underscores the complexity of anxiety disorders and points to potential therapeutic targets for intervention. Future research should continue to elucidate the specific roles of these kinases and their interactions in the context of anxiety, paving the way for more effective treatments.

Transcription factors associated with anxiety

Anxiety disorders are multifaceted conditions that arise from a complex interplay of genetic, environmental, and neurobiological factors. Among the various molecular mechanisms implicated in anxiety, transcription factors play a crucial role in regulating gene expression related to stress responses, emotional regulation, and neuroplasticity. This response synthesizes the current understanding of key transcription factors associated with anxiety, drawing on a range of studies that highlight their roles and mechanisms. One of the prominent transcription factors linked to anxiety is the cAMP response element-binding protein (CREB).

CREB is known to regulate the expression of brain-derived neurotrophic factor (BDNF), which is critical for neuronal survival, differentiation, and synaptic plasticity [30]. Dysregulation of CREB activity has been associated with various mood disorders, including anxiety. For instance, studies have shown that the inhibition of CREB in the forebrain can induce anxiety-like behaviors without affecting spatial learning, suggesting a specific role for CREB in emotional regulation [31]. Furthermore, the expression of CREB is influenced by various signaling pathways, including those activated by stress hormones, which can lead to alterations in anxiety-related behaviors [30].

Another important transcription factor is the nuclear factor of activated T-cells (NFAT), particularly NFATc4. Research has demonstrated that modulation of GABAA receptor signaling through NFATc4 can enhance neurogenesis and reduce anxiety-like behaviors [32]. This indicates that NFATc4 may serve as a potential therapeutic target for anxiety disorders by influencing the balance of excitatory and inhibitory neurotransmission in the brain. The interaction between NFATc4 and GABAA receptors underscores the importance of transcriptional regulation in maintaining emotional homeostasis.

The Kruppel-like factor (KLF) family of transcription factors, particularly KLF9, has also been implicated in anxiety. KLF9 is involved in the late phase of neuronal maturation and has been associated with anxiety-like behaviors in murine models [33,34]. The expression of KLF9 is modulated by stress, and its dysregulation may contribute to the development of anxiety disorders. Additionally, KLF11 has been linked to chronic stress and depressive disorders in humans, further emphasizing the role of KLF transcription factors in emotional regulation [33].

In the context of neuroinflammation and anxiety, the early growth response 1 (EGR1) transcription factor has emerged as a significant player. EGR1 is involved in the regulation of immune responses and has been shown to interact with various inflammatory pathways that can influence anxiety [35]. The dysregulation of EGR1 and its associated pathways may contribute to the anxiety-obesity links observed in various studies, highlighting the intersection between metabolic and emotional health [35].

The transcription factor Pet-1 is crucial for the differentiation of serotonergic neurons and the expression of the serotonin transporter gene (SLC6A4), which is essential for serotonin reuptake [36]. Alterations in serotonin signaling are well-documented in anxiety disorders, and Pet-1's role in regulating serotonergic markers underscores its importance in anxiety pathology. The expression of Pet-1 is influenced by various environmental factors, including stress, which can lead to changes in serotonin levels and anxiety-related behaviors.

Moreover, the transcription factor Gas5 has been implicated in the regulation of anxiety-like behaviors following early-life stress [37]. Gas5 interacts with various coding transcripts that influence anxiety and memory, suggesting a complex regulatory network that involves both coding and non-coding RNAs. The modulation of Gas5 expression may provide insights into the molecular mechanisms underlying stress-induced anxiety.

MicroRNAs (miRNAs) also play a significant role in the regulation of transcription factors associated with anxiety. For instance, miR-132 has been shown to be induced by stress, and its dysregulation can trigger anxiety-related behavior [38]. The expression of miR-132 is tightly regulated by the CREB/CRE transcriptional pathway, indicating that miRNAs can modulate the effects of transcription factors on anxiety. This highlights a layer of complexity in the regulatory networks that govern emotional responses.

The interplay between transcription factors and epigenetic modifications, such as DNA methylation, is another critical aspect of anxiety research. For example, alterations in 5-hydroxymethylcytosine levels in the hippocampus have been linked to stress and anxiety-related behaviors [39]. These epigenetic changes can influence the expression of genes regulated by transcription factors, further complicating the molecular landscape of anxiety disorders.

Conclusion

In summary, transcription factors such as CREB, NFAT, KLFs, EGR1, Pet-1, and Gas5 play pivotal roles in regulating anxiety-related genes. Their interactions with various signaling pathways, epigenetic modifications, and miRNAs underscore the complexity of the molecular mechanisms underlying anxiety disorders. Continued research into these transcription factors and their regulatory networks will enhance our understanding of anxiety and may lead to novel therapeutic strategies.

Bibliography

1. Leibrock C., *et al*. "Akt2 deficiency is associated with anxiety and depressive behavior in mice". *Cellular Physiology and Biochemistry* 32.3 (2013): 766-777.

2. Gitlin LN., *et al*. "Mediators of the impact of a home-based intervention (beat the blues) on depressive symptoms among older African Americans". *Psychology and Aging* 29.3 (2014): 601-611.

3. Opanković A., *et al*. "Predictors of depression, anxiety and stress during the first wave of the covid-19 pandemic: the results of an online survey in Serbia". *Engrami* 43.2 (2021): 53-68.

4. Zhou S and Li X. "Developmental trajectories of symptom-specific anxiety in Chinese preschoolers: the role of maternal anxious rearing behaviors". *Sustainability* 14.24 (2022): 16402.

5. Roseboom PH., *et al*. "Neuropeptide y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism". *Biological Psychiatry* 76.11 (2014): 850-857.

6. Donner N., *et al*. "Serotonergic systems in the balance: crhr1 and crhr2 differentially control stress-induced serotonin synthesis". *Psychoneuroendocrinology* 63 (2016): 178-190.

7. Li J., *et al*. "Involvement of 5-ht1a receptors in the anxiolytic-like effects of quercitrin and evidence of the involvement of the monoaminergic system". *Evidence-Based Complementary and Alternative Medicine* (2016): 6530364.

8. Marinova Z., *et al*. "Region-specific regulation of the serotonin 2a receptor expression in development and ageing in post mortem human brain". *Neuropathology and Applied Neurobiology* 41.4 (2015): 520-532.

9. Smith K and Rudolph U. "Anxiety and depression: mouse genetics and pharmacological approaches to the role of gabaa receptor subtypes". *Neuropharmacology* 62.1 (2012): 54-62.

10. Evenseth LSM., *et al*. "The gabab receptor—structure, ligand binding and drug development". *Molecules* 25.13 (2020): 3093.

11. Grivas V., *et al*. "The metabotropic glutamate 2/3 receptor agonist ly379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety". *European Journal of Pharmacology* 715.1-3 (2013): 105-110.

12. Montoya A., *et al*. "The noradrenergic paradox: implications in the management of depression and anxiety". *Neuropsychiatric Disease and Treatment* 12 (2016): 541-547.

13. Djeungoue-Petga M and Hébert-Chatelain É. "Linking mitochondria and synaptic transmission: the cb1 receptor". *BioEssays* 39.12 (2017).

14. Liu X., *et al*. "Activation of estrogen receptor β in the lateral habenula improves ovariectomy-induced anxiety-like behavior in rats". *Frontiers in Behavioral Neuroscience* 16 (2022): 817859.

15. Jurek B., *et al*. "Differential contribution of hypothalamic mapk activity to anxiety-like behaviour in virgin and lactating rats". *PLoS ONE* 7.5 (2012): e37060.

16. Ko M., *et al*. "B-arrestin–dependent erk signaling reduces anxiety-like and conditioned fear–related behaviors in mice". *Science Signaling* 14.694 (2021): eaba0245.

17. Satoh Y., *et al*. "Erk2 contributes to the control of social behaviors in mice". *Journal of Neuroscience* 31.33 (2011): 11953-11967.

18. Davis MM., *et al*. "Regulator of calmodulin signaling knockout mice display anxiety-like behavior and motivational deficits". *European Journal of Neuroscience* 35.2 (2012): 300-308.

19. Keil M., *et al*. "The role of protein kinase a in anxiety behaviors". *Neuroendocrinology* 103.6 (2016): 625-639.

20. Stefanoska K., *et al*. "Neuronal map kinase p38α inhibits c-jun n-terminal kinase to modulate anxiety-related behaviour". *Scientific Reports* 8.1 (2018): 14296.

21. Dutheil S., *et al*. "High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation". *Neuropsychopharmacology* 41.7 (2015): 1874-1887.

22. Li X., *et al*. "Xiaoyaosan exerts anxiolytic-like effects by down-regulating the tnf-α/jak2-stat3 pathway in the rat hippocampus". *Scientific Reports* 7.1 (2017): 353.

23. Borges G., *et al*. "Activation of extracellular signal-regulated kinases (erk 1/2) in the locus coeruleus contributes to pain-related anxiety in arthritic male rats". *The International Journal of Neuropsychopharmacology* 20.6 (2017): 463-463.

24. Chen Q., *et al*. "Presynaptic long-term potentiation requires extracellular signal-regulated kinases in the anterior cingulate cortex". *Molecular Pain* 16 (2020): 1744806920917245.

25. Park S., *et al*. "The effects of exercise and diet on mental status, insulin signaling pathway, and microbiome in obese mice". *Journal of Exercise Rehabilitation* 18.3 (2022): 171-178.

26. Liu G., *et al*. "Transient inhibition of trkb kinase after status epilepticus prevents development of temporal lobe epilepsy". *Neuron* 79.1 (2013): 31-38.

27. Gu B., *et al*. "A peptide uncoupling bdnf receptor trkb from phospholipase cγ1 prevents epilepsy induced by status epilepticus". *Neuron* 88.3 (2015): 484-491.

28. Wang Y., *et al*. "Oxytocin in the regulation of social behaviors in medial amygdala-lesioned mice via the inhibition of the extracellular signal-regulated kinase signaling pathway". *Clinical and Experimental Pharmacology and Physiology* 42.5 (2015): 465-474.

29. Carrier N and Kabbaj M. "Sex differences in social interaction behaviors in rats are mediated by extracellular signal-regulated kinase 2 expression in the medial prefrontal cortex". *Neuroscience* 212 (2012): 86-92.

30. Hoeffer CA., *et al*. "Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment". *The Journal of Neuroscience* 33.43 (2013): 16930-16944.

31. Vogt MA., *et al*. "Inducible forebrain-specific ablation of the transcription factor creb during adulthood induces anxiety but no spatial/contextual learning deficits". *Frontiers in Behavioral Neuroscience* 8 (2014): 407.

32. Quadrato G., *et al*. "Modulation of gabaa receptor signaling increases neurogenesis and suppresses anxiety through nfatc4". *Journal of Neuroscience* 34.25 (2014): 8630-8645.

33. Li S., *et al*. "Genome-wide alterations in hippocampal 5-hydroxymethylcytosine links plasticity genes to acute stress". *Neurobiology of Disease* 86 (2016): 99-108.

34. Alisch RS., *et al*. "A multi-dimensional characterization of anxiety in monozygotic twin pairs reveals susceptibility loci in humans". *Translational Psychiatry* 7.12 (2017): 1282.

35. Yehuda H., *et al*. "Inversely regulated inflammation-related processes mediate anxiety–obesity links in zebrafish larvae and adults". *Cells* 12.13 (2023): 1794.

36. Albert P., *et al*. "Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-ht1a receptor expression". *Frontiers in Behavioral Neuroscience* 8 (2014): 199.

37. Banerjee D. "Gas5 regulates early life stress-induced anxiety and spatial memory" (2023).

38. Aten S., *et al*. "Mir-132/212 is induced by stress and its dysregulation triggers anxiety-related behavior". *Neuropharmacology* 144 (2019): 256-270.

39. Papale LA., *et al*. "Early-life stress links 5-hydroxymethylcytosine to anxiety-related behaviors". *Epigenetics* 12.4 (2017): 264-276.

Volume 17 Issue 4 April 2025